Just getting into cells is not enough: Mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression

Journal of Controlled Release

Volumn 169, Issue 1-2, 2013, Pages 17-27

  Wonganan, Piyanuch ^a   Lansakara P, Dharmika S P ^a   Zhu, Saijie ^a   Holzer, Melisande ^a   Sandoval, Michael A ^a   Warthaka, Mangalika ^a   Cui, Zhengrong ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cell uptake; Cytarabine; Endocytosis; Hydrolysis; Lysosome; Ribonucleotide reductase

Indexed keywords

CELL UPTAKE; CYTARABINE; ENDOCYTOSIS; LYSOSOME; RIBONUCLEOTIDE REDUCTASE;

BIOMOLECULES; CELLS; CHEMOTHERAPY; CYTOLOGY; HYDROLYSIS; NANOPARTICLES; TUMORS;

DRUG PRODUCTS;

4 (N) STEAROYL GEMCITABINE SOLID LIPID NANOPARTICLE; CLATHRIN; CYTARABINE; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; PROTEIN; RRM1 PROTEIN; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DIFFUSION; DRUG SYNTHESIS; ENDOCYTOSIS; HYDROLYSIS; LUNG CANCER; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DIFFUSION; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; FEMALE; HYDROLYSIS; LIPIDS; LUNG; LUNG NEOPLASMS; MICE; NANOPARTICLES; RIBONUCLEOTIDE REDUCTASES; UP-REGULATION;

EID: 84877057805     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.03.033     Document Type: Article

References (50)

1. J. Long, Y. Zhang, X. Yu, J. Yang, D.G. LeBrun, C. Chen, Q. Yao, and M. Li Overcoming drug resistance in pancreatic cancer Expert Opin. Ther. Targets 15 2011 817 828
2. Y. Nakano, S. Tanno, K. Koizumi, T. Nishikawa, K. Nakamura, M. Minoguchi, T. Izawa, Y. Mizukami, T. Okumura, and Y. Kohgo Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells Br. J. Cancer 96 2007 457 463 (Pubitemid 46215217)
3. J.R. Mackey, S.Y. Yao, K.M. Smith, E. Karpinski, S.A. Baldwin, C.E. Cass, and J.D. Young Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters J. Natl. Cancer Inst. 91 1999 1876 1881
4. V. Heinemann, L.W. Hertel, G.B. Grindey, and W. Plunkett Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine Cancer Res. 48 1988 4024 4031
5. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, and W. Plunkett Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res. 51 1991 6110 6117
6. V. Heinemann, Y.Z. Xu, S. Chubb, A. Sen, L.W. Hertel, G.B. Grindey, and W. Plunkett Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine Mol. Pharmacol. 38 1990 567 572 (Pubitemid 20356209)
7. G. Ferrandina, V. Mey, S. Nannizzi, S. Ricciardi, M. Petrillo, C. Ferlini, R. Danesi, G. Scambia, and M. Del Tacca Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer Cancer Chemother. Pharmacol. 65 2010 679 686
8. W. Gong, X. Zhang, J. Wu, L. Chen, L. Li, J. Sun, Y. Lv, X. Wei, Y. Du, H. Jin, and J. Dong RRM1 expression and clinical outcome of gemcitabine- containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis Lung Cancer 75 2012 374 380
9. S. Palakurthi, V.K. Yellepeddi, and K.K. Vangara Recent trends in cancer drug resistance reversal strategies using nanoparticles Expert Opin. Drug Deliv. 9 2012 287 301
10. X. Dong, and R.J. Mumper Nanomedicinal strategies to treat multidrug-resistant tumors: current progress Nanomedicine (Lond.) 5 2010 597 615
11. W.G. Chung, M.A. Sandoval, B.R. Sloat, P.D. Lansakara, and Z. Cui Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1 J. Control. Release 157 2012 132 140
12. P. Couvreur, B. Stella, L.H. Reddy, H. Hillaireau, C. Dubernet, D. Desmaele, S. Lepetre-Mouelhi, F. Rocco, N. Dereuddre-Bosquet, P. Clayette, V. Rosilio, V. Marsaud, J.M. Renoir, and L. Cattel Squalenoyl nanomedicines as potential therapeutics Nano Lett. 6 2006 2544 2548 (Pubitemid 46076946)
13. L.H. Reddy, C. Dubernet, S.L. Mouelhi, P.E. Marque, D. Desmaele, and P. Couvreur A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types J. Control. Release 124 2007 20 27 (Pubitemid 350103730)
14. S. Rejiba, L.H. Reddy, C. Bigand, C. Parmentier, P. Couvreur, and A. Hajri Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer Nanomedicine 7 2011 841 849
15. R. Rosell, K.D. Danenberg, V. Alberola, G. Bepler, J.J. Sanchez, C. Camps, M. Provencio, D. Isla, M. Taron, P. Diz, and A. Artal Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin. Cancer Res. 10 2004 1318 1325 (Pubitemid 38365223)
16. G.B. Zhang, J. Chen, L.R. Wang, J. Li, M.W. Li, N. Xu, Y. Wang, and J.Z. Shentu RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer Cancer Chemother. Pharmacol. 69 2012 1277 1287
17. S. Nakahira, S. Nakamori, M. Tsujie, Y. Takahashi, J. Okami, S. Yoshioka, M. Yamasaki, S. Marubashi, I. Takemasa, A. Miyamoto, Y. Takeda, H. Nagano, K. Dono, K. Umeshita, M. Sakon, and M. Monden Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer Int. J. Cancer 120 2007 1355 1363
18. H. Xie, W. Jiang, J. Jiang, Y. Wang, R. Kim, and X. Liu Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma Cancer 119 2013 173 181
19. H. Akita, Z. Zheng, Y. Takeda, C. Kim, N. Kittaka, S. Kobayashi, S. Marubashi, I. Takemasa, H. Nagano, K. Dono, S. Nakamori, M. Monden, M. Mori, Y. Doki, and G. Bepler Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma Oncogene 28 2009 2903 2909
20. K. Ohtaka, N. Kohya, K. Sato, Y. Kitajima, T. Ide, M. Mitsuno, and K. Miyazaki Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma Oncol. Rep. 20 2008 279 286
21. T. Wakai, Y. Shirai, J. Sakata, M. Takamura, Y. Matsuda, P.V. Korita, K. Muneoka, M. Sasaki, Y. Ajioka, and K. Hatakeyama Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma Hepatogastroenterology 58 2011 1659 1663
22. L.P. Zhao, C. Xue, J.W. Zhang, Z.H. Hu, Y.Y. Zhao, J. Zhang, Y. Huang, H.Y. Zhao, and L. Zhang Expression of RRM1 and its correlation with sensitivity to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma Chin. J. Cancer 31 2012 476 483
23. B.R. Sloat, M.A. Sandoval, D. Li, W.G. Chung, P.D. Lansakara, P.J. Proteau, K. Kiguchi, J. DiGiovanni, and Z. Cui In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles Int. J. Pharm. 409 2011 278 288
24. Z. Guo Zw, and J.M. Gallo Selective Protection of 2′,2′- Difluorodeoxycytidine (Gemcitabine) J. Org. Chem. 64 1999 8319 8322
25. M.L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, and L. Cattel Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs J. Control. Release 100 2004 331 346 (Pubitemid 39572916)
26. N. Mondal, K.K. Halder, M.M. Kamila, M.C. Debnath, T.K. Pal, S.K. Ghosal, B.R. Sarkar, and S. Ganguly Preparation, characterization, and biodistribution of letrozole loaded PLGA nanoparticles in Ehrlich Ascites tumor bearing mice Int. J. Pharm. 397 2010 194 200
27. S. Zhu, P.D. Lansakara, X. Li, and Z. Cui Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity Bioconjug. Chem. 23 2012 966 980
28. P.D. Lansakara, B.L. Rodriguez, and Z. Cui Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles Int. J. Pharm. 429 2012 123 134
29. L.A. Decosterd, E. Cottin, X. Chen, F. Lejeune, R.O. Mirimanoff, J. Biollaz, and P.A. Coucke Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography Anal. Biochem. 270 1999 59 68 (Pubitemid 29230720)
30. R. Losa, M.I. Sierra, M.O. Gion, E. Esteban, and J.M. Buesa Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 840 2006 44 49 (Pubitemid 44108802)
31. S. Zhu, P. Wonganan, P.D. Lansakara, H.L. O'Mary, Y. Li, and Z. Cui The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression Biomaterials 34 2013 2327 2339
32. J. Rejman, A. Bragonzi, and M. Conese Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes Mol. Ther. 12 2005 468 474 (Pubitemid 41150132)
33. C. Greulich, J. Diendorf, T. Simon, G. Eggeler, M. Epple, and M. Koller Uptake and intracellular distribution of silver nanoparticles in human mesenchymal stem cells Acta Biomater. 7 2011 347 354
34. B. Peng, K. Koga, I. Cardenas, P. Aldo, and G. Mor Phagocytosis of apoptotic trophoblast cells by human endometrial endothelial cells induces proinflammatory cytokine production Am. J. Reprod. Immunol. 64 2010 12 19
35. L. Bildstein, C. Dubernet, V. Marsaud, H. Chacun, V. Nicolas, C. Gueutin, A. Sarasin, H. Benech, S. Lepetre-Mouelhi, D. Desmaele, and P. Couvreur Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway J. Control. Release 147 2010 163 170
36. E. Garcia-Garcia, K. Andrieux, S. Gil, H.R. Kim, T. Le Doan, D. Desmaele, J. d'Angelo, F. Taran, D. Georgin, and P. Couvreur A methodology to study intracellular distribution of nanoparticles in brain endothelial cells Int. J. Pharm. 298 2005 310 314 (Pubitemid 40910734)
37. C.H. Baker, J. Banzon, J.M. Bollinger, J. Stubbe, V. Samano, M.J. Robins, B. Lippert, E. Jarvi, and R. Resvick 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase J. Med. Chem. 34 1991 1879 1884
38. V. Heinemann, L. Schulz, R.D. Issels, and W. Plunkett Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism Semin. Oncol. 22 1995 11 18
39. B.S. Zhou, N.Y. Hsu, B.C. Pan, J.H. Doroshow, and Y. Yen Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells Cancer Res. 55 1995 1328 1333
40. L.P. Jordheim, O. Guittet, M. Lepoivre, C.M. Galmarini, and C. Dumontet Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells Mol. Cancer Ther. 4 2005 1268 1276 (Pubitemid 41149575)
41. A.J. D'Souza, and E.M. Topp Release from polymeric prodrugs: linkages and their degradation J. Pharm. Sci. 93 2004 1962 1979 (Pubitemid 39045479)
42. A.M. Bergman, H.M. Pinedo, V.W. Ruiz van Haperen, G. Veerman, C.M. Kuiper, and G.J. Peters Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs Adv. Exp. Med. Biol. 431 1998 587 590 (Pubitemid 28236841)
43. J.D. Davidson, L. Ma, M. Flagella, S. Geeganage, L.M. Gelbert, and C.A. Slapak An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines Cancer Res. 64 2004 3761 3766 (Pubitemid 38697284)
44. M. Mitsuno, Y. Kitajima, K. Ohtaka, K. Kai, K. Hashiguchi, J. Nakamura, M. Hiraki, H. Noshiro, and K. Miyazaki Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1 Int. J. Oncol. 36 2010 341 349
45. C. Thomssen, M. Schmitt, L. Goretzki, P. Oppelt, L. Pache, P. Dettmar, F. Janicke, and H. Graeff Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer Clin. Cancer Res. 1 1995 741 746
46. S.A. Baldwin, S.Y. Yao, R.J. Hyde, A.M. Ng, S. Foppolo, K. Barnes, M.W. Ritzel, C.E. Cass, and J.D. Young Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes J. Biol. Chem. 280 2005 15880 15887 (Pubitemid 40616710)
47. C.L. Hsu, W. Lin, D. Seshasayee, Y.H. Chen, X. Ding, Z. Lin, E. Suto, Z. Huang, W.P. Lee, H. Park, M. Xu, M. Sun, L. Rangell, J.L. Lutman, S. Ulufatu, E. Stefanich, C. Chalouni, M. Sagolla, L. Diehl, P. Fielder, B. Dean, M. Balazs, and F. Martin Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis Science 335 2012 89 92
48. G. Arreaza, and D.G. Deutsch Deletion of a proline-rich region and a transmembrane domain in fatty acid amide hydrolase FEBS Lett. 454 1999 57 60 (Pubitemid 29296925)
49. K.E. Uhrich, S.M. Cannizzaro, R.S. Langer, and K.M. Shakesheff Polymeric systems for controlled drug release Chem. Rev. 99 1999 3181 3198 (Pubitemid 129583051)
50. T. Cooper, M. Ayres, B. Nowak, and V. Gandhi Biochemical modulation of cytarabine triphosphate by clofarabine Cancer Chemother. Pharmacol. 55 2005 361 368 (Pubitemid 40379260)